MetaVia Inc. (Nasdaq: MTVA) announced on November 14, 2026, the presentation of positive preclinical data from a head-to-head study comparing its drug candidate DA-1726 with retatrutide. The study, conducted in diet-induced obese mice, evaluated the compounds' effects on body weight, food intake, body composition, and metabolic parameters.

DA-1726 is a novel dual oxyntomodulin analog that targets both GLP-1 (GLP1R) and glucagon (GCGR) receptors. The study found that DA-1726 increased hepatic expression of fibroblast growth factor 21 (Fgf21) and liver FGF21 protein levels. It also induced greater expression of genes associated with brown adipose tissue thermogenesis and white adipose tissue browning compared to retatrutide.

Regarding metabolic outcomes, DA-1726 demonstrated greater glucose lowering than retatrutide. At the higher dose, plasma glucose levels decreased by 39.2% for DA-1726, compared to 32.5% for retatrutide. Both compounds improved lipid metabolism, with DA-1726 reducing total cholesterol by 69.3% and LDL cholesterol by 88.4% at the high dose, compared to reductions of 69.0% and 88.1% for retatrutide, respectively.

The data indicated that DA-1726 achieved weight loss comparable to retatrutide with less suppression of food intake. After adjustment relative to controls, body weight reductions were 41.7% for DA-1726 versus 43.6% for retatrutide at the high dose. However, DA-1726 reduced food intake by 31.2%, while retatrutide reduced intake by 41.4%.

MetaVia stated that these findings suggest glucagon receptor-associated metabolic pathways may contribute to DA-1726's weight-loss effects. The company plans to initiate a Phase 2 study in MetALD and ALD in the second half of 2027.